AR093518A1 - Compuestos de pirrolpirimidina como inhibidores de quinasas - Google Patents

Compuestos de pirrolpirimidina como inhibidores de quinasas

Info

Publication number
AR093518A1
AR093518A1 ARP130104233A ARP130104233A AR093518A1 AR 093518 A1 AR093518 A1 AR 093518A1 AR P130104233 A ARP130104233 A AR P130104233A AR P130104233 A ARP130104233 A AR P130104233A AR 093518 A1 AR093518 A1 AR 093518A1
Authority
AR
Argentina
Prior art keywords
substituted
unsubstituted
cycloalkyl
alkyl
independently
Prior art date
Application number
ARP130104233A
Other languages
English (en)
Inventor
Chen Wei
J Loury David
Wang Longcheng
Original Assignee
Pharmacyclics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50728514&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR093518(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacyclics Inc filed Critical Pharmacyclics Inc
Publication of AR093518A1 publication Critical patent/AR093518A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Compuestos que forman enlaces covalentes con la tirosina quinasa de Bruton (Btk). También se describen inhibidores irreversibles de Btk, inhibidores reversibles de Btk. Se divulgan asimismo composiciones farmacéuticas que incluyen a dichos compuestos y métodos para utilizar los inhibidores Btk, ya sea solos o en combinación con otros agentes terapéuticos, para el tratamiento de enfermedades o condiciones autoinmunes, enfermedades o condiciones heteroinmunes, cáncer, inclusive el linfoma, y enfermedades o condiciones inflamatorias. Reivindicación 1: Un compuesto caracterizado porque tiene la estructura de fórmula (1) donde: R¹ es halógeno, -CN, -OR²¹, -N(R²¹)(R²²), -SR²¹, alquilo C₁₋₆ sustituido o no sustituido, alcoxi C₁₋₄ sustituido o no sustituido, heteroalquilo C₁₋₆ sustituido o no sustituido, fenilo sustituido o no sustituido, heteroarilo sustituido o no sustituido o cicloalquilo C₃₋₈ sustituido o no sustituido; G es alquenilo C₂₋₄ sustituido o no sustituido, alquinilo C₂₋₄ sustituido o no sustituido, cicloalquilo C₃₋₈ sustituido o no sustituido, alcoxi C₁₋₄ sustituido o no sustituido, heteroalquilo C₁₋₄ sustituido o no sustituido, heterocicloalquilo C₂₋₇ sustituido o no sustituido, halógeno, -CN, -NO₂, -OR²¹, -OCF₃, -OCH₂F, -OCF₂H, -CF₃, -SCH₃, -N(R²¹)S(=O)₂R²³, S(=O)₂N(R²¹)(R²²), -S(=O)R²³, -S(=O)₂R²³, -C(=O)R²³, -OC(=O)R²³, -CO₂R²¹, N(R²¹)(R²²), -C(=O)N(R²¹)(R²²), -N(R²¹)C(=O)R²³, N(R²¹)C(=O)OR²², N(R²¹)C(=O)N(R²¹)(R²²) o Lᵃ-A; Lᵃ es un enlace, -C(R²¹)(R²²)-, -CR²¹(OR²¹)-, -C(O)-, -O(R²¹)(R²²)-, -S(R²¹)(R²²)-, -C(R²¹)(R²²)S-, -N(R²¹)-, -N(R²¹)C(O)-, -C(O)N(R²¹)-, -N(R²¹)C(O)N(R²¹)-, -O-, -S-, -S(O)-, -S(O)₂-, -N(R²¹)S(O)₂-, o -S(O)₂N(R²¹)-; A es un cicloalquilo sustituido o no sustituido, heterocicloalquilo sustituido o no sustituido, arilo sustituido o no sustituido, o un heteroarilo sustituido o no sustituido; cada R²⁴ es en forma independiente halógeno, -CN, -NO₂, -OH, -OCF₃, -OCH₂F, -OCF₂H, -CF₃, -SCH₃, -N(R²¹)S(=O)₂R²³, S(=O)₂N(R²¹)(R²²), -S(=O)R²³, -S(=O)₂R²³, -C(=O)R²³, -OC(=O)R²³, -CO₂R²¹, N(R²¹)(R²²), -C(=O)N(R²¹)(R²²) -N(R²¹)C(=O)R²³, N(R²¹)C(=O)OR²², N(R²¹)C(=O)N(R²¹)(R²²), alquilo sustituido o no sustituido, alcoxi sustituido o no sustituido, heteroalquilo sustituido o no sustituido, heterocicloalquilo sustituido o no sustituido, o cicloalquilo sustituido o no sustituido; cada R²¹ y R²² es en forma independiente H, alquilo C₁₋₆ sustituido o no sustituido, o cicloalquilo C₃₋₈ sustituido o no sustituido; cada R²³ es cada uno en forma independiente alquilo C₁₋₆ sustituido o no sustituido, o cicloalquilo C₃₋₈ sustituido o no sustituido; n es 0 - 4; Y es un grupo opcionalmente sustituido seleccionado entre alquileno C₁₋₆, heteroalquileno C₁₋₆, arileno C₆₋₁₂, heteroarileno C₃₋₁₂, alquilen C₁₋₆arileno C₆₋₁₂, alquilen C₁₋₆heteroarileno C₃₋₁₂, alquilen C₁₋₆cicloalquileno C₃₋₈, alquilen C₁₋₆heterocicloalquileno C₂₋₇, cicloalquileno C₃₋₈, heterocicloalquileno C₂₋₇cicloalquilen C₃₋₈heterocicloalquileno C₂₋₇ fusionado, y cicloalquilen C₃₋₈heterocicloalquileno C₂₋₇ espiro; Z es -C(=O), -N(Rᵃ)C(=O), -S(=O)ˣ, o -N(Rᵃ)S(=O)ˣ, donde x es 1 ó 2, y Rᵃ es H, alquilo C₁₋₆ sustituido o no sustituido, o cicloalquilo C₃₋₈ sustituido o no sustituido; R⁶ es H, -CN, halógeno, o L-J-W; R⁷ y R⁸ son en forma independiente H, -CN, halógeno, o L-J-W; o R⁷ y R⁸ tomados juntos forman un enlace; L y J son en forma independiente entre sí un enlace, alquileno C₁₋₆ sustituido o no sustituido, cicloalquileno C₃₋₈ sustituido o no sustituido, heteroalquileno C₁₋₆ sustituido o no sustituido, heterocicloalquileno C₂₋₇ sustituido o no sustituido, arileno C₆₋₁₂ sustituido o no sustituido, heteroarileno C₃₋₁₂ sustituido o no sustituido, -CO-, -O-, o -S-; W es H o NR²⁵R²⁶; y R²⁵ y R²⁶ son en forma independiente entre sí H, alquilo C₁₋₆ sustituido o no sustituido, cicloalquilo C₃₋₈ sustituido o no sustituido, heteroalquilo C₁₋₆ sustituido o no sustituido, heterocicloalquilo C₂₋₇ sustituido o no sustituido, arilo C₆₋₁₂ sustituido o no sustituido, o heteroarilo C₃₋₁₂ sustituido o no sustituido; o un solvato farmacéuticamente aceptable, sal farmacéuticamente aceptable, o prodroga farmacéuticamente aceptable del mismo.
ARP130104233A 2012-11-15 2013-11-18 Compuestos de pirrolpirimidina como inhibidores de quinasas AR093518A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261727031P 2012-11-15 2012-11-15

Publications (1)

Publication Number Publication Date
AR093518A1 true AR093518A1 (es) 2015-06-10

Family

ID=50728514

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130104233A AR093518A1 (es) 2012-11-15 2013-11-18 Compuestos de pirrolpirimidina como inhibidores de quinasas

Country Status (24)

Country Link
US (3) US9096604B2 (es)
EP (1) EP2920180A4 (es)
JP (1) JP2015537033A (es)
KR (1) KR20150084923A (es)
CN (1) CN104854107A (es)
AR (1) AR093518A1 (es)
AU (1) AU2013344656A1 (es)
BR (1) BR112015011171A2 (es)
CA (1) CA2890934A1 (es)
CL (1) CL2015001268A1 (es)
CR (1) CR20150263A (es)
DO (1) DOP2015000108A (es)
EA (1) EA201590855A1 (es)
HK (1) HK1215253A1 (es)
IL (1) IL238728A0 (es)
MA (1) MA38183A1 (es)
MX (1) MX2015006168A (es)
NI (1) NI201500067A (es)
PE (1) PE20151495A1 (es)
PH (1) PH12015501067A1 (es)
SG (1) SG11201503842PA (es)
TN (1) TN2015000174A1 (es)
TW (1) TWI522359B (es)
WO (1) WO2014078578A1 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120101113A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
CN102159214A (zh) 2008-07-16 2011-08-17 药品循环公司 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
MX2020004501A (es) 2010-06-03 2021-11-09 Pharmacyclics Llc El uso de inhibidores de la tirosina quinasa de bruton (btk).
WO2012158795A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
EA025496B1 (ru) 2011-05-17 2016-12-30 Принсипиа Биофарма Инк. Ингибиторы тирозинкиназы
EA201490265A1 (ru) 2011-07-13 2014-12-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
HUE052198T2 (hu) 2011-07-21 2021-04-28 Sumitomo Dainippon Pharma Oncology Inc Heterociklusos protein kináz inhibitorok
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
CA3218491A1 (en) 2012-06-04 2013-12-12 Pharmacyclics Llc Crystalline forms of a bruton's tyrosine kinase inhibitor
BR112015001690A2 (pt) 2012-07-24 2017-11-07 Pharmacyclics Inc mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk)
PT2892900T (pt) 2012-09-10 2017-11-06 Principia Biopharma Inc Compostos de pirazolopirimidina como inibidores de cinase
BR112015011171A2 (pt) * 2012-11-15 2017-07-11 Pharmacyclics Inc compostos de pirrolopirimidina como inibidores da quinase
KR102334260B1 (ko) 2013-03-14 2021-12-02 스미토모 다이니폰 파마 온콜로지, 인크. Ｊａｋ2 및 ａｌｋ2 억제제 및 이들의 사용 방법
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
WO2015023703A1 (en) 2013-08-12 2015-02-19 Pharmacyclics, Inc. Methods for the treatment of her2 amplified cancer
SI3052476T1 (sl) * 2013-09-30 2020-12-31 Guangzhou Innocare Pharma Tech Co., Ltd. Substituirani nikotinimidni inhibitorji BTK in njihova priprava in uporaba pri zdravljenju raka, vnetja in avtoimunske bolezni
TN2016000094A1 (en) 2013-09-30 2017-07-05 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase.
WO2015127310A1 (en) 2014-02-21 2015-08-27 Principia Biopharma Inc. Salts and solid form of a btk inhibitor
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
EP3174539A4 (en) * 2014-08-01 2017-12-13 Pharmacyclics, LLC Inhibitors of bruton's tyrosine kinase
WO2016022942A1 (en) 2014-08-07 2016-02-11 Pharmacyclics Llc Novel formulations of a bruton's tyrosine kinase inhibitor
AU2015364335B2 (en) 2014-12-18 2020-11-26 Principia Biopharma Inc. Treatment of pemphigus
AU2016226279B2 (en) 2015-03-03 2021-11-11 Pharmacyclics Llc Pharmaceutical formulations of Bruton's tyrosine kinase inhibtor
TW201718572A (zh) 2015-06-24 2017-06-01 普林斯匹亞生物製藥公司 酪胺酸激酶抑制劑
WO2017027883A1 (en) 2015-08-13 2017-02-16 San Diego State University Research Foundation Atropisomerism for increased kinase inhibitor selectivity
AU2016322063A1 (en) * 2015-09-16 2018-04-12 Loxo Oncology, Inc. Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer
JP2018537502A (ja) * 2015-12-16 2018-12-20 サウザーン リサーチ インスチチュート ピロロピリミジン化合物、キナーゼｌｒｒｋ２阻害剤としての使用、及びその調製方法
CN107513068A (zh) * 2016-06-16 2017-12-26 中国科学院上海药物研究所 一种具有fgfr抑制活性的新型化合物及其制备和应用
KR102391693B1 (ko) 2016-06-29 2022-04-29 프린시피아 바이오파마, 인코퍼레이티드 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴의 변형 방출 제제
AU2017326006B2 (en) * 2016-09-16 2021-10-28 Vitae Pharmaceuticals, LLC. Inhibitors of the menin-MLL interaction
EP3548046A2 (en) 2016-12-03 2019-10-09 Juno Therapeutics, Inc. Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
CN106588937B (zh) 2017-01-16 2018-09-21 东莞市真兴贝特医药技术有限公司 咪唑并吡嗪类化合物及其制备方法和应用
CN106946896B (zh) * 2017-03-30 2019-05-21 成都知普莱生物医药科技有限公司 呋喃并[2,3-d]嘧啶-4-胺衍生物
IT201700099690A1 (it) * 2017-09-06 2019-03-06 Abiogen Pharma Spa Composizione per l’integrazione di calcio
BR112020020246A8 (pt) 2018-04-05 2022-10-18 Sumitomo Dainippon Pharma Oncology Inc Inibidores de cinase axl e uso dos mesmos
EP3773560A4 (en) 2018-04-13 2022-01-19 Sumitomo Dainippon Pharma Oncology, Inc. PIM KINASE INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS AND CANCER-ASSOCIATED FIBROSIS
KR20210038906A (ko) 2018-07-26 2021-04-08 스미토모 다이니폰 파마 온콜로지, 인크. 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
JP2022520361A (ja) 2019-02-12 2022-03-30 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド 複素環式タンパク質キナーゼ阻害剤を含む製剤
JP6960064B2 (ja) * 2019-02-15 2021-11-05 大鵬薬品工業株式会社 ７Ｈ−ピロロ［２，３−ｄ］ピリミジン−４−アミン誘導体
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN111825674A (zh) * 2019-04-22 2020-10-27 上海仕谱生物科技有限公司 嘧啶并五元杂环类化合物及其作为突变型idh2抑制剂的用途
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN113493439B (zh) * 2020-03-20 2022-10-14 深圳市塔吉瑞生物医药有限公司 取代的丙烯酰胺衍生物及其组合物及用途
CN113527300B (zh) * 2020-06-04 2023-02-03 广州百霆医药科技有限公司 布鲁顿酪氨酸蛋白激酶抑制剂
WO2022109551A1 (en) * 2020-11-17 2022-05-27 Relay Therapeutics, Inc. Src inhibitors and uses thereof
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2023078413A1 (zh) * 2021-11-04 2023-05-11 微境生物医药科技(上海)有限公司 Fgfr2抑制剂、及其制备方法和医药用途
US20230277424A1 (en) * 2022-03-03 2023-09-07 Profounda Health And Beauty Inc. Treatment composition for nasal and oral dryness, nosebleeds, and allergy symptoms

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
JPH01167840A (ja) 1987-12-24 1989-07-03 Konica Corp 新規な写真用シアンカプラー
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
US5593997A (en) 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
WO1997049706A1 (en) 1996-06-25 1997-12-31 Novartis Ag SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF
AU748884B2 (en) 1997-03-19 2002-06-13 Abbott Gmbh & Co. Kg Pyrrolo(2,3d)pyrimidines and their use as tyrosine kinase inhibitors
AU3653099A (en) 1998-04-17 1999-11-08 Parker Hughes Institute Btk inhibitors and methods for their identification and use
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
US20050287596A9 (en) 1998-06-26 2005-12-29 Braisted Andrew C Novel ligands and libraries of ligands
US6998233B2 (en) 1998-06-26 2006-02-14 Sunesis Pharmaceuticals, Inc. Methods for ligand discovery
US6306897B1 (en) 1999-03-19 2001-10-23 Parker Hughes Institute Calanolides for inhibiting BTK
SK3812002A3 (en) 1999-09-17 2003-09-11 Abbott Gmbh & Co Kg Pyrazolopyrimidines as therapeutic agents
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
CA2384378C (en) 1999-10-06 2011-05-24 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
US6506769B2 (en) 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
JP2003516351A (ja) 1999-11-30 2003-05-13 パーカー ヒューズ インスティテュート コラーゲン誘導血小板凝集阻害剤
WO2001044258A1 (en) 1999-12-17 2001-06-21 Ariad Pharmaceuticals, Inc. Novel heterocycles
GB0005345D0 (en) 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
US20030040461A1 (en) 2000-10-23 2003-02-27 Mcatee C. Patrick Modulators of Bruton'sTyrosine Kinase and Bruton's Tyrosine Kinase intermediates and methods for their identification and use in the treatment and prevention of osteoporosis and related diseases states
JP2004514732A (ja) 2000-12-06 2004-05-20 ファルマシア・コーポレーション 迅速に分散する医薬組成物
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
US8306897B2 (en) 2001-05-04 2012-11-06 Stockshield, Inc. Method and system for insuring against investment loss
AU2002315389A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
EP2258371A1 (en) 2001-08-10 2010-12-08 Novartis AG Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia
WO2003016338A1 (en) 2001-08-15 2003-02-27 Parker Hughes Institute Crystal structure of the btk kinase domain
JP4391237B2 (ja) 2001-11-21 2009-12-24 サネシス ファーマシューティカルズ， インコーポレイテッド リガンド発見のための方法
US20050084905A1 (en) 2002-03-21 2005-04-21 Prescott John C. Identification of kinase inhibitors
GB2388594A (en) 2002-05-16 2003-11-19 Bayer Ag Imidazo-triazine PDE 4 inhibitors
WO2004014905A1 (en) 2002-08-08 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzimidazole compounds
GB0303910D0 (en) 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
WO2005000197A2 (en) 2003-04-11 2005-01-06 The Regents Of The University Of California Selective serine/threonine kinase inhibitors
US20050008640A1 (en) 2003-04-23 2005-01-13 Wendy Waegell Method of treating transplant rejection
EP1473039A1 (en) 2003-05-02 2004-11-03 Centre National De La Recherche Scientifique (Cnrs) Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis
WO2005014599A1 (en) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
US7393848B2 (en) 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
US8131475B2 (en) 2003-09-03 2012-03-06 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for identifying, diagnosing, and predicting survival of lymphomas
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
TW200530238A (en) 2003-10-15 2005-09-16 Osi Pharm Inc Imidazopyrazine tyrosine kinase inhibitors
US20070196395A1 (en) 2003-12-12 2007-08-23 Mackerell Alexander Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain
BRPI0418031A (pt) 2003-12-22 2007-04-17 Gilead Sciences Inc inibidores de quinase fosfonato-substituìdos
JP2007519742A (ja) 2004-01-26 2007-07-19 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼの阻害剤として有用な組成物
JP2007520559A (ja) 2004-02-03 2007-07-26 アボット・ラボラトリーズ 治療薬としてのアミノベンゾオキサゾール類
MY139689A (en) 2004-07-20 2009-10-30 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
US20060079494A1 (en) 2004-09-27 2006-04-13 Santi Daniel V Specific kinase inhibitors
AU2005290028A1 (en) 2004-09-28 2006-04-06 Janssen Pharmaceutica, N.V. Substituted dipiperdine CCR2 antagonists
BRPI0517619A (pt) 2004-11-10 2008-10-14 Cgi Pharmaceuticals Inc entidades quìmicas de imidazo[1,2-a] pirazin-8-ilaminas, suas composições farmacêuticas, uso dos referidos compostos na preparação de medicamento, processo de preparação de medicamento e métodos de utilização dos referidos compostos
GB0425035D0 (en) 2004-11-12 2004-12-15 Novartis Ag Organic compounds
TW200716551A (en) 2005-03-10 2007-05-01 Cgi Pharmaceuticals Inc Certain substituted amides, method of making, and method of use thereof
ES2358344T3 (es) 2005-05-13 2011-05-09 Irm, Llc Compuestos y composiciones como inhibidores de proteína quinasa.
DK1893612T3 (da) 2005-06-22 2011-11-21 Plexxikon Inc Pyrrol [2,3-B]pyridin-derivater som proteinkinasehæmmere
US20070065449A1 (en) 2005-09-16 2007-03-22 Claire Verschraegen Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab)
EP1957491A2 (en) 2005-11-12 2008-08-20 Boehringer Ingelheim International GmbH Pyrrolo (2,3-b) pyridine derivatives useful as tec kinase inhibitors
US7625880B2 (en) 2006-01-13 2009-12-01 Pharmacyclics, Inc. Inhibitors of tyrosine kinases and uses thereof
WO2007089911A2 (en) 2006-01-30 2007-08-09 The Scripps Research Institute Methods for detection of circulating tumor cells and methods of diagnosis of cancer in a mammalian subject
MX2008012928A (es) 2006-04-04 2009-03-06 Univ California Antagonistas de pi3-cinasa.
MX2008014450A (es) 2006-05-18 2009-03-09 Mannkind Corp Inhibidores de cinasa intracelular.
ES2585902T3 (es) 2006-09-22 2016-10-10 Pharmacyclics Llc Inhibidores de tirosina cinasa de Bruton
WO2008121742A2 (en) 2007-03-28 2008-10-09 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
WO2008054827A2 (en) 2006-11-03 2008-05-08 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
NL2000640C2 (nl) 2007-03-05 2008-09-08 Stichting Wetsus Ct Of Excelle Werkwijze en systeem voor het zuiveren van een vloeistof.
US20120065201A1 (en) 2007-03-28 2012-03-15 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US20120101113A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US20090010911A1 (en) 2007-04-06 2009-01-08 Iowa State University Research Foundation, Inc. Methods and compositions for affecting cyclophilin a regulation of kinases in modulating cellular activities
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
JP5600063B2 (ja) 2007-10-19 2014-10-01 セルジーン アビロミクス リサーチ， インコーポレイテッド ヘテロアリール化合物およびその使用
WO2009053269A1 (en) 2007-10-23 2009-04-30 F. Hoffmann-La Roche Ag Novel kinase inhibitors
US8426441B2 (en) 2007-12-14 2013-04-23 Roche Palo Alto Llc Inhibitors of bruton's tyrosine kinase
US20150152115A1 (en) 2007-12-27 2015-06-04 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
DK2361248T3 (en) 2008-06-27 2019-01-14 Celgene Car Llc Heteroberl compounds and uses thereof
CN102159214A (zh) 2008-07-16 2011-08-17 药品循环公司 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
RU2542963C2 (ru) 2008-09-05 2015-02-27 Селджен Авиломикс Рисерч,Инк., Способ определения ингибитора, ковалентно связывающего целевой полипептид
US8426428B2 (en) * 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
JP5656976B2 (ja) 2009-04-29 2015-01-21 ローカス ファーマシューティカルズ インコーポレイテッド ピロロトリアジン化合物
WO2011034907A2 (en) 2009-09-16 2011-03-24 Avila Therapeutics, Inc. Protein kinase conjugates and inhibitors
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
HUE030720T2 (en) 2010-05-31 2017-06-28 Ono Pharmaceutical Co Purinone derivative as btk kinase inhibitor
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
MX2020004501A (es) * 2010-06-03 2021-11-09 Pharmacyclics Llc El uso de inhibidores de la tirosina quinasa de bruton (btk).
AU2011269989B2 (en) 2010-06-23 2014-12-11 Hanmi Science Co., Ltd. Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
EP3144298A1 (en) 2010-08-10 2017-03-22 Celgene Avilomics Research, Inc. Besylate salt of a btk inhibitor
EA025496B1 (ru) * 2011-05-17 2016-12-30 Принсипиа Биофарма Инк. Ингибиторы тирозинкиназы
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
CA3218491A1 (en) 2012-06-04 2013-12-12 Pharmacyclics Llc Crystalline forms of a bruton's tyrosine kinase inhibitor
DK2861599T3 (da) * 2012-06-18 2020-03-02 Principia Biopharma Inc Reversible kovalente pyrrolo- eller pyrazolopyrimidiner, der er nyttige til behandling af cancer og autoimmunsygdomme
BR112015001690A2 (pt) 2012-07-24 2017-11-07 Pharmacyclics Inc mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk)
BR112015011171A2 (pt) 2012-11-15 2017-07-11 Pharmacyclics Inc compostos de pirrolopirimidina como inibidores da quinase
DK3003309T3 (da) 2013-05-30 2020-12-14 Infinity Pharmaceuticals Inc Behandling af cancer med PI3-kinase-isoform modulatorer
WO2015017812A1 (en) 2013-08-02 2015-02-05 Pharmacyclics, Inc. Methods for the treatment of solid tumors
KR20160066554A (ko) 2013-10-25 2016-06-10 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나제 억제제 및 면역요법을 이용한 치료
CN106008514A (zh) 2014-01-29 2016-10-12 苏州晶云药物科技有限公司 依鲁替尼的新晶型及其制备方法
WO2015127261A1 (en) 2014-02-21 2015-08-27 Pharmacyclics, Inc. Biomarkers for predicting response of dlbcl to treatment with ibrutinib
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations

Also Published As

Publication number Publication date
WO2014078578A1 (en) 2014-05-22
US20150239897A1 (en) 2015-08-27
MX2015006168A (es) 2015-08-10
MA38183A1 (fr) 2017-03-31
TW201425315A (zh) 2014-07-01
DOP2015000108A (es) 2015-06-30
BR112015011171A2 (pt) 2017-07-11
NI201500067A (es) 2016-02-15
PE20151495A1 (es) 2015-10-23
AU2013344656A1 (en) 2015-06-04
TN2015000174A1 (en) 2016-10-03
US20160375026A1 (en) 2016-12-29
CR20150263A (es) 2015-08-24
EA201590855A1 (ru) 2015-11-30
EP2920180A1 (en) 2015-09-23
US9540385B2 (en) 2017-01-10
TWI522359B (zh) 2016-02-21
CN104854107A (zh) 2015-08-19
CA2890934A1 (en) 2014-05-22
EP2920180A4 (en) 2016-04-13
JP2015537033A (ja) 2015-12-24
HK1215253A1 (zh) 2016-08-19
IL238728A0 (en) 2015-06-30
US9096604B2 (en) 2015-08-04
US20140142126A1 (en) 2014-05-22
CL2015001268A1 (es) 2015-07-10
PH12015501067A1 (en) 2015-08-10
SG11201503842PA (en) 2015-06-29
KR20150084923A (ko) 2015-07-22

Similar Documents

Publication Publication Date Title
AR093518A1 (es) Compuestos de pirrolpirimidina como inhibidores de quinasas
AR103297A1 (es) Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina
AR097862A1 (es) Inhibidores de tirosina quinasa de bruton
AR086983A1 (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
AR111295A1 (es) Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr)
AR101175A1 (es) Imidazopiridinas e imidazopirazinas como inhibidores de lsd1
AR105845A1 (es) Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4
AR089175A1 (es) Inhibidores de pak para el tratamiento de trastornos de proliferacion celular
AR101174A1 (es) Imidazopirazinas como inhibidores de lsd1
AR085958A1 (es) 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas para el tratamiento de trastornos del cns y cancer
AR106652A1 (es) Compuestos para tratar la esclerosis lateral amiotrófica
AR091424A1 (es) Compuestos triciclicos sustituidos como inhibidores de receptores del factor de crecimiento del fibroplasto (fgfr)
AR088810A1 (es) Moduladores del receptor mas acoplado a la proteina g utiles en el tratamiento de trastornos cardiovasculares y composiciones farmaceuticas que los contienen
AR085283A1 (es) Antagonistas de hepcidina a base de sulfonaminoquinolina
AR087984A1 (es) Derivados biciclicos de dihidroquinolina-2-ona
AR116114A1 (es) Amidas heterocíclicas de entre 5 y 7 miembros como inhibidores de jak
AR092538A1 (es) Inhibidores de girasa triciclica
AR095359A1 (es) Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina
CO6420344A2 (es) Derivados de triazolopiridina como inhibidores de proteínas cinasas activadas por mitogeno p38 (map)
AR092809A1 (es) 3,5-diaminopirazol como inhibidor de quinasa
AR107042A1 (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso
AR085398A1 (es) Ureas asimetricas y usos medicos de las mismas
AR100714A1 (es) Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaespiro undecano que tienen actividad multimodal contra el dolor
AR110282A1 (es) Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1
AR093758A1 (es) Inhibidores de aril lactama quinasa

Legal Events

Date Code Title Description
FB Suspension of granting procedure